Eiger BioPharmaceuticals reports Phase 2 results for lonafarnib at ILC
Eiger BioPharmaceuticals announced additional lonafarnib data from the LOWR HDV Program presented at The International Liver Congress in Amsterdam. After 24 weeks of treatment, all-oral lonafarnib-based regimens suppressed Hepatitis Delta Virus-RNA below the limit of quantitation in 36% of patients, and 60% achieved ALT normalization. The addition of PEG IFN to LNF 25 mg BID + RTV suppressed HDV-RNA below the limit of quantitation in 80% of patients, and 78% achieved ALT normalization. In patients treated for 48 weeks with triple therapy of PEG IFN + LNF 25 mg BID + RTV, PCR-negativity was achieved in 67% of patients at the end of treatment. Additional dosing regimens were also explored in the LOWR program. Anti-HDV activity was observed in all regimens through Week 24 on treatment. HDV viral load returned to baseline in a majority of these patients by Week 24 of post-treatment, suggesting longer-term treatment of all-oral LNF + RTV or triple combination of LNF + RTV + PEG IFN may be necessary to achieve sustained antiviral suppression. Hepatitis Delta is the most aggressive form of viral hepatitis.